{"id":30308,"date":"2025-03-25T12:31:43","date_gmt":"2025-03-25T04:31:43","guid":{"rendered":"https:\/\/flcube.com\/?p=30308"},"modified":"2025-03-25T12:31:44","modified_gmt":"2025-03-25T04:31:44","slug":"chongqing-zhifei-acquires-51-stake-in-chenan-bio-for-rmb593-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30308","title":{"rendered":"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million"},"content":{"rendered":"\n

Chongqing Zhifei Biological Co., Ltd (SHE: 300122<\/a>), the distribution partner for US giant Merck’s Gardasil in China, has announced the acquisition of a 51% stake in compatriot firm Chongqing Chenan Biopharmaceutical Co., Ltd. for RMB 593 million (USD 82 million). This strategic move aims to expand Zhifei’s presence in the chronic disease therapy market.<\/p>\n\n\n\n

Chenan Bio’s Profile<\/strong>
Chenan Bio, incubated by Zhirui Investment in 2015, is a high-tech company specializing in the research, development, and production of therapeutic drugs for chronic diseases, including diabetes and obesity. The company has a robust pipeline of over ten investigational programs.<\/p>\n\n\n\n

Product Pipeline<\/strong>
Chenan Bio’s product pipeline includes a liraglutide biosimilar prepared for market filing, generic versions of semaglutide (for diabetes) and insulin degludec with completed Phase III trials, and copycats of semaglutide (for weight loss) and insulin degludec, insulin aspart at Phase III stages. This diverse portfolio positions Chenan Bio as a significant player in the chronic disease treatment sector.<\/p>\n\n\n\n

Strategic Implications<\/strong>
The acquisition by Zhifei Biological underscores its commitment to expanding its offerings in chronic disease therapies. By leveraging Chenan Bio’s robust R&D capabilities and product pipeline, Zhifei aims to enhance its market competitiveness and provide broader treatment options for patients with chronic conditions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck’s Gardasil…<\/p>\n","protected":false},"author":1,"featured_media":30311,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3892,39,120,86,879,878],"class_list":["post-30308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-chenan-biopharmaceutical","tag-diabetes","tag-merck","tag-obesity","tag-she-300122","tag-zhifei-biological"],"yoast_head":"\nChongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck's Gardasil in China, has announced the acquisition of a 51% stake in compatriot firm Chongqing Chenan Biopharmaceutical Co., Ltd. for RMB 593 million (USD 82 million). This strategic move aims to expand Zhifei's presence in the chronic disease therapy market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30308\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million\" \/>\n<meta property=\"og:description\" content=\"Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck's Gardasil in China, has announced the acquisition of a 51% stake in compatriot firm Chongqing Chenan Biopharmaceutical Co., Ltd. for RMB 593 million (USD 82 million). This strategic move aims to expand Zhifei's presence in the chronic disease therapy market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30308\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T04:31:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-25T04:31:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2505-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30308#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30308\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million\",\"datePublished\":\"2025-03-25T04:31:43+00:00\",\"dateModified\":\"2025-03-25T04:31:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30308\"},\"wordCount\":218,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30308#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2505-png.webp\",\"keywords\":[\"Chenan Biopharmaceutical\",\"Diabetes\",\"Merck\",\"Obesity\",\"SHE: 300122\",\"Zhifei Biological\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30308#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30308\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30308\",\"name\":\"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30308#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30308#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2505-png.webp\",\"datePublished\":\"2025-03-25T04:31:43+00:00\",\"dateModified\":\"2025-03-25T04:31:44+00:00\",\"description\":\"Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck's Gardasil in China, has announced the acquisition of a 51% stake in compatriot firm Chongqing Chenan Biopharmaceutical Co., Ltd. for RMB 593 million (USD 82 million). This strategic move aims to expand Zhifei's presence in the chronic disease therapy market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30308#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30308\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30308#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2505-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2505-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30308#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million - Insight, China's Pharmaceutical Industry","description":"Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck's Gardasil in China, has announced the acquisition of a 51% stake in compatriot firm Chongqing Chenan Biopharmaceutical Co., Ltd. for RMB 593 million (USD 82 million). This strategic move aims to expand Zhifei's presence in the chronic disease therapy market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30308","og_locale":"en_US","og_type":"article","og_title":"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million","og_description":"Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck's Gardasil in China, has announced the acquisition of a 51% stake in compatriot firm Chongqing Chenan Biopharmaceutical Co., Ltd. for RMB 593 million (USD 82 million). This strategic move aims to expand Zhifei's presence in the chronic disease therapy market.","og_url":"https:\/\/flcube.com\/?p=30308","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-25T04:31:43+00:00","article_modified_time":"2025-03-25T04:31:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2505-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30308#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30308"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million","datePublished":"2025-03-25T04:31:43+00:00","dateModified":"2025-03-25T04:31:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30308"},"wordCount":218,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30308#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2505-png.webp","keywords":["Chenan Biopharmaceutical","Diabetes","Merck","Obesity","SHE: 300122","Zhifei Biological"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30308#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30308","url":"https:\/\/flcube.com\/?p=30308","name":"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30308#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30308#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2505-png.webp","datePublished":"2025-03-25T04:31:43+00:00","dateModified":"2025-03-25T04:31:44+00:00","description":"Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck's Gardasil in China, has announced the acquisition of a 51% stake in compatriot firm Chongqing Chenan Biopharmaceutical Co., Ltd. for RMB 593 million (USD 82 million). This strategic move aims to expand Zhifei's presence in the chronic disease therapy market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30308#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30308"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30308#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2505-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2505-png.webp","width":1080,"height":608,"caption":"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30308#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2505-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30308"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30308\/revisions"}],"predecessor-version":[{"id":30312,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30308\/revisions\/30312"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30311"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}